Workflow Analysis Comparing Manual and Automated Specimen Processing for Mass Spectrometry–Based Vitamin D Testing

Tacker, Danyel H.; Topardo, Joyce; Mahaffey, Carole; Perrotta, Peter L.

doi:10.1309/lmzl47en6kdodmxj

Cited by 11 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With a market available this can translate to a corresponding increase in profits (Ceroni, 2009). A research laboratory investing in automation can improve the efficiency of its researchers (Hawker and Schlank, 2000;Schneider, 2018) with machinery able to achieve a greater rate of experimental output than a manual based alternative (Tacker et al, 2014;Price et al, 2015;Choi et al, 2018). It should be noted that an automated protocol need not take less time from start-to-finish to result in higher output than the manual alternative, as long as it demands less human intervention (Reed et al, 2018).…”

Section: Laboratory Efficiencymentioning

confidence: 99%

Automation in the Life Science Research Laboratory

Holland

Davies

2020

Front. Bioeng. Biotechnol.

101

View full text Add to dashboard Cite

Section: Laboratory Efficiencymentioning

confidence: 99%

Automation in the Life Science Research Laboratory

Holland

Davies

2020

Front. Bioeng. Biotechnol.

101

View full text Add to dashboard Cite

“…Thus, application of these techniques seems to be an excellent option for developing multiple biomarker panels, which is of paramount importance, especially for highly heterogeneous diseases like bladder cancer. Mass spectrometry-based analytical methods are already in use in clinical practice, for assessing the presence of specific drugs [79][80][81] or metabolites in bodily fluids, 82 or for the identification of microorganisms. 83 Moving towards assessment of urinary peptides or proteins for clinical diagnosis is, therefore, achievable with currently available technologies.…”

Section: Multi-marker Panelsmentioning

confidence: 99%

Developing proteomic biomarkers for bladder cancer: towards clinical application

et al. 2015

View full text Add to dashboard Cite

Clinical use of proteomic biomarkers has the potential to substantially improve the outcomes of patients with bladder cancer. An unmet clinical need evidently exists for noninvasive biomarkers, which might enable improvements in both the diagnosis and prognosis of patients with bladder cancer, as well as improved monitoring of patients for the presence of recurrence. Urine is considered the optimal noninvasive source of proteomic biomarkers in patients with bladder cancer. Currently, a number of single-protein biomarkers have been detected in urine and tissue using a variety of proteomic techniques, each having specific conceptual considerations and technical implications. Promising preclinical data are available for several of these proteins; however, the combination of single urinary proteins into multimarker panels might better encompass the molecular heterogeneity of bladder cancer within this patient population, and prove more effective in clinical use.

show abstract

“…The frequent use of manual methods in the analysis of samples in our laboratory significantly extends the time taken to render results. The contribution of the automatic method of analysis to the reduction of the delay in rendering results has already been demonstrated: with faster turnaround and elimination of wasteful practices, automated processes facilitate time savings [30].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Clinical Laboratory Tests’ Turnaround Time in a Tertiary Hospital in Democratic Republic of the Congo

Alain¹,

Rostin²,

Joël³

et al. 2021

JBM

View full text Add to dashboard Cite

The delay in the delivery of laboratory results can be fatal and can even lead to the death of patients. This study was conducted at the clinical laboratory of the University Hospital of Kinshasa (UHK) from October 2020 to April 2021, aimed to evaluate the laboratory tests' turnaround time (TAT) and to identify reasons for delay. TAT was quantified using a time and motion analysis approach. The evaluation of TAT consisted of comparing the overall intra-lab TAT with the suggested TAT using student t-test at 95% confidence intervals. Brainstorming was the root cause analysis tool used for identifying reasons for delay. In this study, the laboratory tests' TATs were significantly higher (p < 0.001) comparing to international guidelines (60 minutes) and customers' suggested TAT (120 minutes). Only 0.98% of the samples were reported within 60 minutes of patient reception and 1.47% within 120 minutes, i.e. an outlier rate of 98.5%. Root causes of delay related to Machinery, Management, Manpower, Materials, Method and Milieu. Because of many reasons, the laboratory is not meeting the established TAT. Preventive and curative measures must be undertaken to reduce the delay and improve the TAT.

show abstract

Workflow Analysis Comparing Manual and Automated Specimen Processing for Mass Spectrometry–Based Vitamin D Testing

Abstract: Automated specimen preparation should be considered when batch sizes reach 35 to 40 specimens per day.

Cited by 11 publications

References 4 publications

Automation in the Life Science Research Laboratory

Automation in the Life Science Research Laboratory

Developing proteomic biomarkers for bladder cancer: towards clinical application

Evaluation of Clinical Laboratory Tests’ Turnaround Time in a Tertiary Hospital in Democratic Republic of the Congo

Contact Info

Product

Resources

About